Affordable Access

Chemotherapy of schistosomiasis: present and future

Authors
Journal
Current Opinion in Chemical Biology
1367-5931
Publisher
Elsevier
Publication Date
Volume
11
Issue
4
Identifiers
DOI: 10.1016/j.cbpa.2007.05.031
Disciplines
  • Medicine

Abstract

Schistosomiasis is a chronic parasitic disease in tropical and subtropical regions and is associated with a variety of clinical syndromes that may lead to severe morbidity. Over the past 25 years, therapy and control of schistosomiasis has come to rely heavily on one drug, praziquantel (PZQ). This reliance is of concern should widespread treatment failure arise, particularly as measures are being undertaken to increase PZQ's availability. This review summarizes the use, possible modes of action and limitations of PZQ, and recent attempts to derive synthetic analogs. Alternative artemisinin-based chemotherapies that have shown applicability in certain disease settings are also similarly examined. Looking forward, the review highlights some of the more experimental anti-schistosomals being evaluated (e.g. the trioxolanes), including those where knowledge of the parasite target (e.g. cysteine proteases and hemozoin formation) is more defined.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Chemotherapy of schistosomiasis: present and futur...

on Current Opinion in Chemical Bi... August 2007

Chemotherapy::Present and Future

on Otolaryngologic Clinics of Nor...

[Present and future of chemotherapy].

on [Chiryō] [Therapy] 1963

Chemotherapy of Schistosomiasis present and past.

on Journal of the Egyptian Societ... April 1998
More articles like this..